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Abstract: PNC-27, a 32-residue peptide that contains an HDM-2 binding domain and a cell-penetrating
peptide (CPP) leader sequence kills cancer, but not normal, cells by binding to HDM-2 associated
with the plasma membrane and induces the formation of pores causing tumor cell lysis and necrosis.
Conformational energy calculations on the structure of PNC-27 bound to HDM-2 suggest that 1:1
complexes form between PNC-27 and HDM-2 with the leader sequence pointing away from the
complex. Immuno-scanning electron microscopy was carried out with cancer cells treated with
PNC-27 and decorated with an anti-PNC-27 antibody coupled to 6 nm gold particles and an antiHDM-2 antibody linked to 15 nm gold particles. We found multiple 6 nm- and 15 nm-labeled gold
particles in approximately 1:1 ratios in layered ring-shaped structures in the pores near the cell surface
suggesting that these complexes are important to the pore structure. No pores formed in the control,
PNC-27-treated untransformed fibroblasts. Based on the theoretical and immuno-EM studies, we
propose that the pores are lined by PNC-27 bound to HDM-2 at the membrane surface with the
PNC-27 leader sequence lining the pores or by PNC-27 bound to HDM-2.
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1. Introduction
PNC-27 and its shorter analog peptide (PNC-28) are peptides that selectively lyse the
membranes of cancer cells, resulting in the necrosis of a variety of cancer cell lines and
primary human tumors, but not untransformed cells [1–5]. PNC-27 contains residues 12–26
of the HDM-2-binding domain of p53 attached to a leader sequence (termed the membrane
residency peptide or MRP) that normally induces the transport of peptides attached to it
across the cell and nuclear membranes [1–3]. We found that this peptide induced rapid
necrosis of cancer cells rather than apoptosis [1–4]. Induction of tumor cell necrosis was
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not induced by the isolated p53 12–26 peptide, by the leader sequence alone, or by both
separate peptides together, suggesting that both domains must be covalently linked for
tumor cell killing [3,4].
Transmission electron microscopy (TEM) of cancer cells treated with PNC-27 revealed
that transmembrane pores formed in these cells [3,4]. This finding correlated with the results
of the determination of the three-dimensional structure of PNC-27 by two-dimensional
NMR that showed an amphipathic alpha-helix-loop-alpha-helix structure that has been
found for a number of pore-forming, membrane-active polypeptides [6].
In further structural studies [7], we found that the three-dimensional structure of
residues 17–26 of PNC-27 was superimposable on that determined by X-ray crystallography
for the same residues of a p53 peptide (p53 residues 17–29) bound to the p53 binding domain
of HDM-2 (HDM-2 residues 25–109) [8]. Since PNC-27 lacks residues 27–29, as were present
in the X-ray crystal structure of the p53 19–29-HDM-2 complex, and contains p53 residues
12–16 and the entire leader sequence, that were not present in the X-ray crystal structure,
the question arises as to whether PNC-27 binds to HDM-2 in a manner similar to that of
the binding of the p53 peptide to HDM-2 in the X-ray crystal structure [8]. An important
aspect of this question is the disposition of the leader sequence since this domain of PNC-27
has no apparent relationship to the binding of PNC-27 to HDM-2 but is critical to pore
formation [3,4].
The selective cytotoxic pore-forming effect of PNC-27 for cancer cells is linked to
elevated expression of cell surface HDM-2 compared only with low or undetectable levels
in the membranes of untransformed cells [7] and its colocalization with HDM-2 in cancer
cell membranes [7].
The interaction of PNC-27 with HDM-2 in cancer cell membranes, which is critical
for peptide-induced tumor cell necrosis, was shown in experiments with untransformed
human breast epithelial cells, which do not normally express HDM-2 in their membranes
and are not susceptible to PNC-27-induced lysis [7]. Transfection of a vector encoding
HDM-2 expressing a membrane localization (CAAX box) sequence into these cells resulted
in extensive tumor cell necrosis when they were incubated with PNC-27. This effect was
not observed in cells transfected with an empty vector or vector encoding HDM-2 with its
p53 binding domain deleted but with its nuclear localization signal present, suggesting
that PNC-27 binds to HDM-2 in the cancer cell membrane [7], inducing tumor cell death.
Since EM studies suggested that PNC-27 induces transmembrane pore formation
uniquely in cancer cells and our further studies suggested that PNC-27 must bind to HDM2 in the cancer cells’ membranes to induce tumor cell lysis, we now investigate, using
conformational energy analysis, whether PNC-27 can form a low energy complex with the
HDM-2 binding domain that is similar in structure for p53 residues 19–29 as determined
in the X-ray crystal structure [8] and what the disposition of the leader sequence is in this
complex. In addition, using high-resolution immuno-scanning electron microscopy, we
have directly imaged PNC-27-induced transmembrane pores in cancer cell membranes and
show that they contain complexes of PNC-27 with HDM-2.
2. Materials and Methods
2.1. Materials
PNC-27 and PNC-29. PNC-27 contains a segment from human p53, residues 12–26, that
is involved in the binding of p53 to HDM-2 connected to a membrane penetrating sequence
called the membrane residency peptide (MRP). The sequence is H-Pro-Pro-Leu-Ser-Gln-GluThr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-LysVal-Gln-Arg-Gly-OH. The MRP is shown in italics. This peptide (1 g) was synthesized using
solid-phase methods (Shaanxi Zhongbang Pharma-Tech Corp., NanguanZhengjie, Xi’an,
China) and was >95% pure by HPLC and mass spectrographic analysis. Similarly, the
negative control peptide, PNC-29 [1,2,4], containing the X13 peptide from cytochrome
P450 (bold) attached to the MRP (italics), H-Met-Pro-Phe-Ser-Thr-Gly-Lys-Arg-Ile-Met-LeuGly-Glu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH, was
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likewise synthesized by solid-phase methods (Biopeptides, San Diego, CA, USA) and was
>95% pure by the same techniques.
Streptolysin O. This was purchased from Sigma (St. Louis, MO, USA) and used directly.
Cells. MIA-PaCa-2 (human pancreatic carcinoma) and A2058 (human melanoma) cells
and untransformed human fibroblasts (AG13145) were purchased from the American Type
Culture Collection (ATCC) (Manassas, VA, USA) and placed in the appropriate media as
described previously [1]. BMRPA1.TUC-3 (rat pancreatic cancer) cells were grown in our
laboratory using methods described previously [2–4,7].
2.2. Methods
Predicted Structure of PNC-27 Bound to the HDM-2 p53 Peptide Binding Domain
Residues 25–109. We superimposed the atoms of our 2D-NMR-determined structure for
PNC-27 [6] for residues 17–26 of the p53 HDM-2-binding segment of PNC-27 on the
corresponding coordinates for the atoms, from the X-ray crystal structure of the p53 peptide
residues 17–29 complexed with residues 25–109 of HDM-2 [5] as deposited in the Protein
Data Bank as 1YCR, using PyMol (PyMol Molecular Graphics System Web Site). Unlike
in the previous study [6], we performed the superposition using the whole peptide. After
performing the supposition of the PNC-27 structure on the corresponding structure of
the p53 peptide in the HDM-2 binding site, we removed the 17–29 peptide so that the
complex of the HDM-2 structure with our least-squares best-fit structure for PNC-27 was
the starting structure for energy minimization using Maestro (Schrodinger Release 2016-2,
Version 10.6, New York, NY, USA). The latter process was carried out using the method of
steepest descents allowing the atoms of both the PNC-27 peptide and HDM-2 to change [9].
After energy convergence, we then superimposed the coordinates for residues 17–26 of the
resulting energy-minimized structure with those of the corresponding residues of the X-ray
structure for the 17–29 residue peptide bound to HDM-2 to determine if the structure of
the residues of PNC-27 was still superimposable.
Transmission Electron Microscopy (TEM)
TEM-Cells. Cells (1 × 106 ) were grown in 6-well dishes overnight; the spent medium
was removed, and the cells were washed with PBS and treated at 37 ◦ C with PNC-27 at
pre-determined concentrations. After 10 min of PNC-27 treatment, the cells were washed
and fixed in 3% buffered paraformaldehyde supplemented with 1% glutaraldehyde for
2 h at which time they were scraped into PBS and centrifuged into a pellet. The pellet was
embedded in 6% agar in PBS followed by osmication and dehydration through sequential
passages in increasing concentrations of ethanol (50–100%). The pellet was embedded in
50% resin for 1 h followed by 100% resin embedment overnight. Samples were processed for
TEM by preparing 60 nm thin sections that were stained with uranyl acetate and examined
in a Zeiss EM10 TEM.
Immunogold TEM. Cells (1 × 106 ) were grown in 6-well TCD overnight when spent
medium was removed; the cells were then washed with PBS and treated at 37 ◦ C with PNC27 in PBS. After 10 min, the cells were washed and fixed in 3% buffered paraformaldehyde
supplemented with 0.1% glutaraldehyde for 1.5 h. After extensive washing, quenching
with glycine and NaBH4, the cells were incubated overnight at 4 ◦ C with anti-p53 mAb
clone DO-1 that recognizes p53 residues 11–25, overlapping with the PNC-27 p53 residues
12–26 domain (Active Motif, Carlsbad, CA, USA) or monoclonal rabbit anti-HDM -2 (Pierce,
Rockford, IL, USA), each at 5 µg/mL. After removal of unbound Ab and washing with
PBS, the cells were incubated for 6 h with 6 nm gold-conjugated GαM F(ab’)2 (Abcam,
Cambridge, MA, USA) or 15 nm gold-conjugated GαR F(ab’)2 (Abcam). After extensive
washing, cells were post-fixed in 1% glutaraldehyde in cacodylate buffer (0.113 M, pH7.2)
overnight when the fixed cells were scraped into PBS, centrifuged into a pellet, washed
in cacodylate buffer, and post-fixed in 1% osmium tetraoxide. Following embedding and
sectioning as described above, the thin sections were stained with uranyl acetate and
examined in a Zeiss EM10 TEM.
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Streptolysin Control. In a separate set of control experiments, A2058 human melanoma
cells were treated with streptolysin O (Santa Cruz Biotechnology, Dallas, TX, USA), Rabbit
IgG against SLO (RαSLO IgG) (Santa Cruz Biotechnology) and secondary antibody, i.e.,
6 nm gold particles conjugated to Goat IgG against RIgG (gold-GαRIgG) was obtained
from Electron Microscopic Sciences (EMD, Ft. Washington, PA, USA). In a prior series of
preliminary dose-response experiments over a 30 min incubation period at RT, 10 hemolytic
units (HU)/mL were established as the LD50 in A2058 cells. After 10 min of SLO-treatment
at room temperature, unbound SLO was washed off with ice-cold PBS and the cells were
fixed and processed as described above. The cells were then successively stained with
RαSLO IgG and 6 nm gold-derivatized GαR IgG, post-fixed in 1% glutaraldehyde in
cacodylate buffer, scraped and processed for TEM on a Zeiss EM10 TEM as described above.
Photography was performed using an automated digital camera providing a scale bar for
each picture that accompanied the preparation of the present photographs and defines, in
any comparisons, the correct sizes of cells and cellular organelles.
Scanning Electron Microscopy (SEM). MIA-PaCa-2 cells were grown on glass cover
slips and treated with PNC-27 (150 µg/mL) for 3–5 min at 37 ◦ C. Control cells were left
untreated in the same buffer conditions. At the end of the incubation period, the cells were
fixed in 3% glutaraldehyde in 0.113 M cacodylate buffer (pH7.4) at 37 ◦ C in a water bath
for 15 to 30 min, followed by overnight fixation at room temperature. The cells were then
immuno-gold stained with antibodies against PNC-27 and HDM2 as described for TEM
immuno-gold experiments. The cells were then dehydrated by moving each cover slip
through a series of increasing alcohol concentrations from 50% to 90% (2 incubations each
for 5 min) and 100% (2 incubations, 10 min each). The cover slips with the dehydrated
cells were then mounted on metal stubs, platinum sputter-coated and viewed in a LEO
1550 SEM, capable of detecting high back-scattering of the gold particles, equipped with
an automated digital camera that inserted scale bars according to the magnifications used
during photographic recording of the results. Identical procedures were carried out for
untransformed AG-13145 human fibroblasts.
Temperature Dependence of PNC-27 Tumor Cell Cytotoxicity. A series of individual
96-well tissue culture dishes (TCDs) were prepared and cells (5000/well) were seeded
into each well. To precisely control the incubation temperatures, the TCDs with the cells
were floated in water baths set to 17 ◦ C and 37 ◦ C. The temperatures in the wells were
continuously controlled by thermometers placed directly into a buffer-containing well of
each TCD. Once the medium remained stable at the preset temperature, the original culture
medium was removed and PBS containing the concentrations of peptide indicated was
added. After 30 min incubation at the predetermined temperature, the cytotoxic effect of
PNC-27 was calculated in percent from the amount of released LDH (cell supernatant)
in the wells, and the amount of LDH remaining in the cells (cell lysates) as described
previously (2–5; 7). All experiments (n = 3) were carried out using triplicate sets of wells.
Three cell lines were employed in this study: Rat pancreatic cancer BMRPA1.TUC-3 cells,
Hu-melanoma (A2058) cells, and Hu-pancreatic cancer MIA PaCa-2 cells.
Cytotoxicity Studies Involving Incubation at 17 ◦ C followed by incubation and Cytotoxicity Assay at 37 ◦ C. From BMRPA1-TUC-3 pancreatic cancer cells that had been
incubated with PNC-27 at 17 ◦ C for 30 min, the supernatant was removed, the cells were
washed with PBS (17 ◦ C), which was followed by re-incubation in only PBS (37 ◦ C) at 37 ◦ C,
while another set of cells in triplicate continued incubation at 17 ◦ C. Thirty minutes later,
cytotoxicity was measured, as described previously [2–5,7], in all wells.
3. Results
PNC-27 Is Accommodated in the HDM-2 Binding Site. PNC-27 is a peptide that
contains residues 12–26 of the p53 protein that are involved in the binding of p53 to HDM-2
attached to the leader sequence on its carboxyl terminal end. Since the residues of the p53
peptide domain that make contact with residues in the binding site of HDM-2 are near
to the carboxyl terminal end of this peptide domain [8], there is the possibility that the
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PNC-27 Induction of Transmembrane Pores in Cancer Cells. In prior publications [3,4],
we presented the results of TEM showing pores that formed in cancer cell membranes
even after short exposures of the MCF-7 breast cancer cells to PNC-27 [3] and MIA-PaCa-2
human pancreatic cancer cells to PNC-28. Figure 2 shows the effects of PNC-27 on MIAPaCa-2 cells after 10 min of incubation. Both panels A and B of this figure show untreated
MIA-PaCa-2 cells with intact plasma (blue arrows) and nuclear (yellow arrows) membranes.
Panels C and D show that, after several minutes of treatment of the cells with PNC-27, pores
form in the plasma membrane (red arrows, Panel C) and vacuoles form in mitochondria
(orange arrows, Panel D). As controls, these cells were incubated with a control peptide,
PNC-29, known to have no effect on either cancer or normal cells [3,4], and, as shown in
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PNC-27 Is Present in Pores in Cancer Cell Membranes. To determine whether
PNC-27 occurs in transmembrane pores in cancer cells, we utilized antibodies linked to
homogeneous-sized gold particles. This technique has been used to show that membranelysing proteins, such as streptolysin O (SLO), are directly involved in transmembrane pore
formation [11].
To evaluate whether there are similarities in pore structures induced by PNC-27 to
that of known pore-forming agents (i.e., SLO), we incubated MIA-PaCa-2 cells with SLO
(10 hemolytic units/mL) for 10 min, washed, and then incubated the treated cells with rabbit
IgG against SLO, followed by incubation with 6 nm diameter gold-labeled goat anti-rabbit
IgG. The cells were washed and fixed for TEM. Results are shown in the Supplementary
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anti-rabbit IgG. The cells were washed and fixed for TEM. Results are shown in the Supplementary
Materials,
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stained for 6 nm gold-labeled PNC-27 labeled (red arrows) as in part A and with anti-HDM-2 antibody labeled by 15 nm gold-labeled secondary antibodies (yellow arrow). The blue arrows point to
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Figure 4. SEM: Cancer vs. untransformed cells treated with PNC-27. (A): Scanning electron microFigure 4. SEM: Cancer vs. untransformed cells treated with PNC-27. (A): Scanning electron migraph of untreated MIA-PaCa-2 cells. (B): High power scanning electron micrograph of the memcrograph of untreated MIA-PaCa-2 cells. (B): High power scanning electron micrograph of the
brane of an untreated MIA-PaCa-2 cell in (A). (C): Scanning electron micrograph of the membrane
membrane of an untreated MIA-PaCa-2 cell in (A). (C): Scanning electron micrograph of the membrane of a typical MIA-PaCa-2 cell from cells that were treated with PNC-27 for 10 min. The holes are
transmembrane pores surrounded by spherical bodies that protrude out from the membrane into the
external environment (blue arrows). (D): Scanning electron micrograph of untreated untransformed
human fibroblasts (AG-13145). (E): Scanning electron micrograph of the membrane of a fibroblast
treated with PNC-27 showing no pores. low mag. (×5000); high mag. (×100,000).

By applying the specificity of the immunostaining reaction to the structure of the pore,
it can be stated that the two heads likely represent part of the external rim of the pore
formed by the assembly of the PNC-27-HDM2 complexes entering into the pore complexes.
As noted above, the longitudinal section of the PNC-27-HDM2 pore complex is very similar
to that of channels of SLO [11]. The morphological similarity of SLO pores and PNC-27-
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HDM2 pore complexes, together with the fatal outcome for cells whose plasma membranes
have been penetrated and made leaky by the insertion of SLO pores, suggests a similar
functional consequence to the formation of PNC-27-HDM-2 pore complexes as the cause of
rapid cancer cell necrosis induced by PNC-27.
Three-Dimensional Structure of PNC-27-Induced Transmembrane Pores Containing PNC-27-HDM-2 Complexes. To achieve a better view of the pore structure and its
relation to the cell surface topography and the participating molecules (PNC-27 and HDM2), we performed scanning (three-dimensional) EM (SEM) on cancer cells treated with
PNC-27 to examine the structure of these pores not visible in the TEM studies. In these
experiments, MIA-PaCa-2 cells were treated with PNC-27 for 3 min after which they were
processed for SEM.
Figure 4 shows untreated MIA-PaCa-2 cells (Figure 4A) and a high-power view of the
membrane of one of these cells (Figure 4B). Figure 4C shows the membrane of one of the
MIA-PaCa-2 cells treated with PNC-27. The membrane is covered with pores surrounded
by well-defined spherical structures (blue arrows) some of which appear to protrude from
the membrane into the external environment.
As a control for these studies, we treated the untransformed cell line, AG-13145 human
skin fibroblasts, with PNC-27 under identical conditions to those used for MIA-PaCa-2 cells.
As shown in Figure 4D (untreated fibroblasts) and 4E (fibroblasts treated with PNC-27),
these cells, under SEM, were found to have neither pores nor spherical bodies surrounding
pores as found in Figure 4C. This finding confirms that the membrane of untransformed
fibroblasts remains smooth after being treated with PNC-27 and does not contain any pores
or pores surrounded by spherical structures seen in the cancer cells.
To determine the spatial relationship of PNC-27 and HDM-2 in the structure of PNC-27induced pores, we obtained high-resolution back-scattered SEM with gold immunostaining,
as described for the experiments performed for Figure 3B. The objective was to obtain 3-D
images of the cancer cell’s surface membrane and the pore structures.
Figure 5 shows the plasma membrane of PNC-27-treated MiaPaCa-2 cells at four
successively increasing magnifications. In Panel A, the surface membrane appears rough
and stippled as opposed to the untreated cells (Figure 4A). At higher magnification, as
shown in Figure 5B–D, numerous see-through pore-like channels are seen distributed over
the plasma membrane. These pore-like channels are surrounded by limiting rings, which
appear as donuts or partial donuts, and appear to be projecting out from the membrane
level, constituting the “bulky heads” that project beyond the cancer cell membrane shown
in Figure 3B.
Although the appearance of the pores in Figure 5B–D is similar to those shown in
Figure 4C, the white-colored appearance of the spherical structures in Figure 5 is due to the
high back-scattering of light by the gold particles. If the gold atoms attached to the two
antibody systems labeling PNC-27 and HDM-2 had not been present, the white spherical
structures surrounding the pores in Figure 5 would have a gray to black color, making
it impossible to identify these structures. We have confirmed this conclusion in control
experiments in which cells treated with PNC-27 were then incubated only with secondary
antibodies and then processed for SEM. Therefore, we conclude that the spherical structures
shown in Figure 4C contain complexes of PNC-27 and HDM-2.
Higher magnification of the ring structures shown in Figure 5B is shown in Figure 5C
where two typical surrounding ring structures are seen to be composed of gold-containing
particles that are 6 nm (red arrows) and 15 nm (yellow arrows) in diameter, indicating the
presence of PNC-27 and HDM-2, respectively; these appear to be formed as 1:1 complexes.
Virtually all of the donut-like structures in Figure 5C are decorated with these complexes
surrounding the pores. These donut-like rings enclose transmembrane pores that, when
measured, have inside diameters of similar sizes of 28–44 nm with an average diameter of
34.5 ± 5.6 nm (n = 100), similar to the inner pore diameter found in Figure 3B.
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factor in spatial availability that can lead to dissociation of these complexes during SEM
processing. To help confirm that the spherical particles contain gold-labeled proteins, we
measured the diameter of these particles on the EM images and found that they are 7.69 nm
for the nominal 6 nm gold particle and 15.05 nm for the 15 nm gold particles.
The unlabeled holes in the PNC-27-treated membrane of these cancer cells may
have been caused by dissociation of the pore structure from the membrane or may have
resulted secondarily from disruption of the plasma membrane due to the inability of
the cells to maintain their fluid and ion balance and energy production. Since PNC27-HDM-2 complexes surround most of the pores, these observations provide strong
support for the notion that PNC-27 molecules inserted into the plasma membrane of
cancer cells bind to HDM-2, and the resulting complexes associate to form structured
transmembrane pores.
Steps in the Formation of Transmembrane Pores. It has been proposed for poreforming proteins, such as SLO, that the process of pore formation involves two steps: one
in which the protein binds to the membrane and, then in a second step, the protein diffuses
through the lipid membrane, forming the transmembrane pores [11–13]. The first binding
step appears to be a temperature-independent process (within about 4–35 ◦ C), while the
diffusion step appears to be strongly temperature-dependent over the same temperature
range [11–13]. The temperature dependence is likely due to decreased lipid mobility as the
temperature is lowered [11–13]. The first step may involve major changes in the domain
structure of the protein as has been modeled for pneumolysin [14,15]. In this process,
protein molecules may associate with one another independently of the membrane and
form isolated pores or “arcs” in the cell membrane [14,15].
Therefore, to further define the process of pore formation induced by PNC-27, we
studied the temperature dependence of its ability to bind to HDM-2 and induce pore
formation in the light of these previous studies. In these experiments, we assayed the
release of LDH as a measure of pore formation since this correlates with tumor cell killing
and transmembrane pore formation. Figure 6A shows the temperature dependence of PNC27-induced pore formation for two different cell lines MIA-PaCa-2 (pancreatic cancer) and
A2058 (melanoma). As can be seen in Figure 6A, there is a strong temperature dependence
for induction of pore formation as observed by the release of LDH from the treated cells.
Dose-response experiments at 37 ◦ C reach 100 percent tumor cell killing at concentrations
above 100 µg/mL as measured by LDH release. Lowering the temperature by just 12 ◦ C to
25 ◦ C results in a large decrease in cell killing, and, at 17 ◦ C, there is virtually no cell killing
(Figure 6A).
If the above-described model for pore formation holds, PNC-27 should be bound
to HDM-2 but the individual complexes would be unable to aggregate into pores at
the low temperatures. To test this hypothesis, we incubated rodent pancreatic cancer
BMRPA1.TUC-3 cells at 17 ◦ C with PNC-27 at the same concentrations as used for the
temperature experiments shown in Figure 6A, and washed out the excess peptide. The
cells were then warmed to 37 ◦ C over 30 min. The results are shown in Figure 6B.
Cell killing was enhanced as the PNC-27 molecules had already been inserted into the
membrane of the cells, and by increasing the temperature to 37 ◦ C, the monomeric
peptide molecules were then able to freely move within the membrane and aggregate to
form the pores in a shorter time period. These results suggest that monomeric PNC-27
molecules, like SLO, bind to its target in a relatively temperature-independent manner
and then form pores by diffusion of the PNC-27-HDM-2 complexes to form aggregates
in the cell membrane in a temperature-dependent process.
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4. Discussion
PNC-27 Induces Transmembrane Pores in Cancer Cells that Contain PNC-27-HDM2 Complexes. The results shown in Figures 2–5 suggest that PNC-27 induces the formation
of transmembrane pores lined at the outer membrane surface with PNC-27-HDM-2 complexes. Many of these complexes appear to protrude beyond the membrane surface into
the extracellular environment, i.e., the “bulky heads”, seen in the TEM experiments shown
in Figure 3B, as well as the spherically shaped particles surrounding the pores in the membrane seen in the SEM experiments of Figures 4 and 5. Although, due to different angles of
cutting cell samples, it is not possible to establish the exact stoichiometry of the complexes,
Figure 5 suggests that PNC-27 and HDM-2 form approximately one to one complexes.
Relationship of PNC-27-HDM-2 Complexes to Pore Structure. In a recent study [16],
it was found that PNC-27 induces tumor cell necrosis of a number of human and mouse
acute myelogenous leukemia (AML) cells. All of these cells expressed HDM-2 in their
cell membranes with which PNC-27 was found to co-localize as we found in our prior
experiments on human solid tissue tumors [7]. Transmission electron micrographic studies
of these cells that had been treated with PNC-27 were found to have transmembrane pores.
In separate experiments [16] in the same study, PNC-27 was found to induce interaction of
HDM-2 with the membrane protein cadherin resulting in its ubiquitination and cleavage.
Transfection of these cells with siRNAs against expression of cadherin resulted in markedly
decreased cell killing induced by PNC-27 leading to the conclusions that PNC-27-induced
pore formation was caused by HDM-2-promoted degradation of cadherin and that PNC27-HDM-2 complexes were not involved in the formation of pores.
Our present results on solid tissue tumors suggest that the pores induced by PNC-27
in the solid tissue cancer cells, as revealed by high-resolution images of the structure of the
pores, are lined with PNC-27-HDM-2 complexes and are essential to pore structure as we
discuss further below.
Possible Structure of Pores. PNC-27 adopts an amphipathic alpha-helix-loop-alphahelix conformation in solution [6]. This type of structure occurs in a number of membraneactive peptides such as mellitin [17] and magainin [18]. A model for transmembrane
pore formation induced by amphipathic peptides has been proposed [19] in which the
amphipathic peptide forms pores in several stages. In the first stage, the peptide lies along
the outer cell membrane wherein the positively charged peptide residues (such as those
that occur in the MRP) interact with phosphate negative charges in the phospholipids
of the membrane. In a second step, the peptide inserts into the membrane such that the
hydrophobic residues interact with lipids in the lipid bilayer while the charged and polar
residues form intermolecular complexes with one another lining the interior of the pore. In
this step, parts or all of the peptide can undergo a helix-to-extended conformation to span
the membrane [19].
Though PNC-27 is an amphipathic peptide, it is clear that it forms complexes with
HDM-2 in the transmembrane pores. Furthermore, we have found that, in normal pancreatic acinar (BMRPA1) cells, PNC-27 traverses the membrane and localizes to the nucleus [4].
No pores form in these or other untransformed cells treated with PNC-27 (see Figure 4E
showing no pores in untransformed fibroblasts treated with PNC-27). Thus, a prerequisite
for PNC-27-induced transmembrane pore formation is that it complexes with membranebound HDM-2. In addition, most of the hydrophobic face of the PNC-27 that is composed
of residues 6–15 (corresponding to residues 17–26 of p53) in the HDM-2 binding domain,
from our structure calculations, is bound deeply within the binding pocket of HDM-2
(Figure 1) and would not be available to interact with membrane bilayer lipids.
These considerations raise the question as to the possible arrangements of the PNC27-HDM-2 complexes in the pore. In particular, do PNC-27-HDM-2 complexes line the
pores from the surface of the membrane down to the cytosolic side of the membrane? The
existence of PNC-27-HDM-2 complexes contained within the membrane seems unlikely
since this complex would have to exist in a largely hydrophobic lipid bilayer environment.
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Figure 7. Model for formation of transmembrane pores induced by PNC-27. This figure is divided
Figure 7. Model for formation of transmembrane pores induced by PNC-27. This figure is divided
into two parts: on the left, a model is shown as a triangular pie-shaped section of the cancer cell
into two parts: on the (left), a model is shown as a triangular pie-shaped section of the cancer cell
membrane, in which PNC-27, shown as the blue (the HDM-2-binding portion) and red (MRP or
leader sequence) bent α-helical structure, binds to HDM-2, shown as the large red transmembrane
molecules at low temperature (17 ◦ C), but the complex does not form pores. At higher temperature
(37 ◦ C), as shown in the center and (right) of the figure, these PNC-27-HDM-2 complexes coalesce
to form transmembrane pores such as the one in the middle of the figure. In this figure, HDM-2 is
shown as spanning the entire membrane. Alternatively, PNC-27 may bind directly to HDM-2 near
the cell surface and HDM-2 may not extend deeply into membrane, but rather the MRP may extend
through the membrane in an extended conformation such that the pores would be lined by the MRP.

Possible Role of the MRP in PNC-27. Alternatively, if HDM-2 is expressed on the cell
surface and does not traverse the cell membrane, complexes of HDM-2 and PNC-27 could
coalesce such that the MRP (leader sequence) (red residues in Figure 1) would span the
membrane and line the pores. The energy-minimized structure in Figure 1 shows that the
MRP (red structure in Figure 1) is not involved in binding to HDM-2, projecting away from
the complex, and appears to be free to interact with other molecules. This conclusion must
be qualified by the consideration that only the p53-binding domain of HDM-2, residues
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25–109, bound to a p53 peptide has been subjected to X-ray crystallographic analysis (13).
Full-length HDM-2 has 491 amino acids. The location of the MRP in full-length HDM-2 is
therefore unknown. However, if the MRP segment does project away from the complex, it
may be in a position to line the pores.
In this model, if the MRP retains its α-helical structure, the maximal length of the
MRP sequence (residues 19–32) would be approximately 21 Å, or, if all residues 16–32 of
the MRP were α-helical, 29 Å. Model lipid bilayer membranes have been found to span
distances of around 40 Å [20], which would be longer than the length of an MRP α-helix.
If, however, the MRP could undergo a transition to an all-extended (β) structure [19], the
length of this segment would increase to approximately 63 Å, allowing this segment to
span the bilayer. In this case, the pores would be lined by multiple MRP domains, each
extending down through the membrane from individual PNC-27-HDM-2 complexes at the
outer surface of the membrane.
The results of our experiments on the temperature dependence of PNC-27-induced
tumor cell killing (Figure 6) suggest that, as with pore-forming proteins such as streptolysin,
PNC-27 induces pore formation in two discrete steps: a binding step in which it complexes
with HDM-2 in the cancer cell membrane and a subsequent diffusion step in which the
PNC-27-HDM-2 complexes fuse together in the cell membrane to form the pores. However,
the driving force for pore formation induced by streptolysin appears to be a general
affinity for lipid and cholesterol in the lipid bilayer of the cell membrane [21]. In contrast,
pore formation induced by PNC-27 in the cancer cell membrane is due to its affinity for
membrane-bound HDM-2 and has no apparent relationship to affinity for lipid.
Implications for Cancer Therapy. In contrast to most other anti-cancer agents, PNC-27
induces tumor cell necrosis by inducing transmembrane pore formation which is independent of intracellular processes, e.g., it does not depend on the presence of specific
signal transduction pathways, the action of p53 and/or of other apoptosis-inducing agents,
and/or avoidance of MDR gene products but depends only on the expression of HDM-2
in the cancer cell membrane. This feature gives this peptide the ability to kill multiple
types of cancers regardless of what pro-mitotic intracellular processes occur in these cells.
It also differs from other anti-cancer agents whose purpose is to block the binding of p53 to
HDM-2 in the nucleus allowing p53 to function in activating apoptosis in these cells [22].
These agents are effective in cancer cells that express wild-type p53 but cannot be used
to treat cancer cells that contain homozygously deleted or homozygously mutated p53.
In contrast, PNC-27 has been found to kill cancer cell lines that are p53 homozygously
deleted [1,2]. In addition, at least some of these agents appear to inhibit the growth of
normal cells [23]. We have found that PNC-27 does not block the viability or growth of
many different untransformed cell lines, none of which express any appreciable levels of
HDM-2 in their membranes, and has been found not to have off-target effects in vivo [16,24].
Thus, this peptide appears to be a potentially strong and effective anti-cancer agent in
treating human cancers by a novel mechanism.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/biomedicines10050945/s1, Figure S1: TEM of cancer and normal
cells treated with control peptide PNC-29 and effective peptide PNC-27, respectively. MIAPaCa-2
cancer cells were treated with PNC-29 (A: whole cells view on the left and B: cytoplasmic view on
the right). AG13145 untransformed human primary fibroblasts (C) and BMRPA1 normal pancreatic
acinar cells (D) were treated with PNC-27. Intact plasma membrane and mitochondria is observed in
all control TEM studies with cancer cells treated with control peptide PNC-29 or untransformed cells
treated with PNC-27; Figure S2: Immuno-TEM of streptolysin O (SLO) pores. A: Human pancreatic
cancer MIAPaCa-2 cells were treated with SLO, fixed and followed by staining with primary Ab
against SLO, SLO mAb IgG, and a secondary Ab, 6 nm-gold-GαM IgG. B: The electron micrograph
on the left shows ring structures of the SLO pore on the plasma membrane, which are magnified on
the right (bars indicating magnification). Multiple gold particles decorate the rings, which indicate
the location of SLO molecules.
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